• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MIANSERIN Drug Record

  • Summary
  • Interactions
  • Claims
  • MIANSERIN chembl:CHEMBL6437 Approved

    Alternate Names:

    MIANSERIN
    J16.389I
    NORVAL®
    (+-)-ATHYMIL
    1,2,3,4,10,14B-HEXAHYDRO-2-METHYLDIBENZO(C,F)PYRAZINO(1,2-A)AZEPINE
    MIANSERINE
    MIANSERYNA
    MIANSERINA
    MIANSERINUM
    ORG GB 94
    drugbank:06148
    pubchem.compound:4184
    chemidplus:24219-97-4
    rxcui:6929
    chembl:CHEMBL6437

    Drug Info:

    Year of Approval not approved by the fda
    Drug Class antidepressive agents, second-generation
    FDA Approval not approved by the FDA
    Drug Class small molecule
    Drug Indications Antidepressive Agents, Second-Generation
    (2 More Sources)

    Publications:

    Dekeyne et al., 2006, Discriminative stimulus properties of the selective and highly potent alpha2-adrenoceptor agonist, S18616, in rats: mediation by the alpha2A subtype, and blockade by the atypical antidepressants, mirtazapine and mianserin., Neuropharmacology
    Grinshpoon et al., 2000, Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients., Eur. Psychiatry
    Petrascheck M et al., 2007, An antidepressant that extends lifespan in adult Caenorhabditis elegans., Nature
    Nowak et al., 1983, Interaction between mianserin, an antidepressant drug, and central H1- and H2-histamine-receptors: in vitro and in vivo studies and radioreceptor assay., Neuropharmacology
    Csaba et al., 2003, Prolonged effect of the tricyclic antidepressant, mianserin on the serotonin and histamine content of young rats' white blood cells and mast cells. A case of late-imprinting., Pharmacol. Res.
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Mihara K et al., 1997, The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients., J Clin Psychopharmacol
    Dahl ML et al., 1994, Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism., Clin Pharmacol Ther
    Tacke U et al., 1992, Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations., J Clin Psychopharmacol
    Kawanishi C et al., 2004, Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study., Eur J Clin Pharmacol
  • MIANSERIN   HTR4

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18033297


    Sources:
    DTC

  • MIANSERIN   HSPA5

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MIANSERIN   HTR2C

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    11004734


    Sources:
    TdgClinicalTrial TEND

  • MIANSERIN   HTR3A

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18033297


    Sources:
    DTC

  • MIANSERIN   ADRA2A

    Interaction Score: 0.26

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    16814817


    Sources:
    TdgClinicalTrial TEND

  • MIANSERIN   HRH1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    6302549 11004734 12967590


    Sources:
    TdgClinicalTrial TEND

  • MIANSERIN   HTR2A

    Interaction Score: 0.18

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11004734


    Sources:
    TdgClinicalTrial TEND

  • MIANSERIN   CYP2D6

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9408809 8062494 1527229 14652703


    Sources:
    PharmGKB

  • MIANSERIN   DRD1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MIANSERIN   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528


    Sources:
    PharmGKB

  • TEND: MIANSERIN

    • Version: 01-August-2011

    Alternate Names:
    MIANSERIN Primary Drug Name

    Drug Info:
    Drug Class antidepressive agents, second-generation
    Year of Approval not approved by the fda

    Publications:

  • TdgClinicalTrial: MIANSERIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antidepressive Agents, Second-Generation
    Drug Class small molecule
    FDA Approval not approved by the FDA

    Publications:

  • DTC: MIANSERIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL6437 ChEMBL Drug ID

    Drug Info:

    Publications:
    Petrascheck M et al., 2007, An antidepressant that extends lifespan in adult Caenorhabditis elegans., Nature

  • PharmGKB: mianserin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Kawanishi C et al., 2004, Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study., Eur J Clin Pharmacol
    Tacke U et al., 1992, Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations., J Clin Psychopharmacol

  • TTD: Mianserin

    • Version: 2020.06.01

    Alternate Names:
    D0R6RO TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL6437

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21